First City Capital Management Inc. cut its holdings in Eli Lilly and Company (NYSE:LLY) by 0.4% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 23,386 shares of the company’s stock after selling 99 shares during the quarter. Eli Lilly and comprises 1.4% of First City Capital Management Inc.’s portfolio, making the stock its 17th largest position. First City Capital Management Inc.’s holdings in Eli Lilly and were worth $1,925,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in LLY. BlackRock Inc. boosted its stake in Eli Lilly and by 2,628.5% in the first quarter. BlackRock Inc. now owns 62,260,488 shares of the company’s stock valued at $5,236,731,000 after acquiring an additional 59,978,664 shares during the last quarter. Dodge & Cox boosted its stake in Eli Lilly and by 22,094.9% in the second quarter. Dodge & Cox now owns 5,991,952 shares of the company’s stock valued at $493,138,000 after acquiring an additional 5,964,955 shares during the last quarter. Renaissance Technologies LLC boosted its stake in Eli Lilly and by 91.1% in the second quarter. Renaissance Technologies LLC now owns 5,694,905 shares of the company’s stock valued at $468,691,000 after acquiring an additional 2,714,505 shares during the last quarter. Vanguard Group Inc. boosted its stake in Eli Lilly and by 3.3% in the first quarter. Vanguard Group Inc. now owns 68,597,006 shares of the company’s stock valued at $5,769,694,000 after acquiring an additional 2,181,701 shares during the last quarter. Finally, Winslow Capital Management LLC boosted its stake in Eli Lilly and by 79.7% in the first quarter. Winslow Capital Management LLC now owns 3,875,968 shares of the company’s stock valued at $326,008,000 after acquiring an additional 1,719,538 shares during the last quarter. 76.61% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another domain, it was illegally copied and reposted in violation of US & international copyright & trademark law. The correct version of this report can be accessed at https://www.watchlistnews.com/first-city-capital-management-inc-sells-99-shares-of-eli-lilly-and-company-lly/1717162.html.

Shares of Eli Lilly and Company (NYSE:LLY) opened at $83.18 on Tuesday. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.38 and a quick ratio of 1.03. Eli Lilly and Company has a 52 week low of $64.18 and a 52 week high of $89.09. The stock has a market cap of $91,590.00, a price-to-earnings ratio of 20.27, a price-to-earnings-growth ratio of 1.83 and a beta of 0.34.

Eli Lilly and (NYSE:LLY) last issued its quarterly earnings results on Tuesday, October 24th. The company reported $1.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.03 by $0.02. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.27%. The firm had revenue of $5.66 billion for the quarter, compared to analyst estimates of $5.52 billion. During the same period in the previous year, the business earned $0.88 EPS. The company’s revenue was up 9.0% compared to the same quarter last year. equities research analysts anticipate that Eli Lilly and Company will post 4.21 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 8th. Shareholders of record on Wednesday, November 15th will be paid a $0.52 dividend. The ex-dividend date is Tuesday, November 14th. This represents a $2.08 annualized dividend and a yield of 2.50%. Eli Lilly and’s payout ratio is currently 99.05%.

A number of equities analysts have issued reports on LLY shares. Leerink Swann cut shares of Eli Lilly and from an “outperform” rating to a “market perform” rating and reduced their price objective for the company from $93.00 to $90.00 in a research note on Wednesday, July 26th. BMO Capital Markets reissued an “underperform” rating and set a $73.00 price target on shares of Eli Lilly and in a research report on Wednesday, July 26th. Oppenheimer Holdings, Inc. cut shares of Eli Lilly and from an “outperform” rating to a “market perform” rating and set a $90.00 price target on the stock. in a research report on Wednesday, July 26th. UBS AG cut shares of Eli Lilly and to a “hold” rating and set a $85.00 price target on the stock. in a research report on Wednesday, July 26th. Finally, TheStreet raised shares of Eli Lilly and from a “c+” rating to a “b+” rating in a research report on Tuesday, July 25th. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating and ten have issued a buy rating to the company. Eli Lilly and currently has a consensus rating of “Hold” and an average price target of $89.76.

In other Eli Lilly and news, SVP Alfonso G. Zulueta sold 2,003 shares of Eli Lilly and stock in a transaction on Friday, November 10th. The shares were sold at an average price of $83.67, for a total value of $167,591.01. Following the sale, the senior vice president now directly owns 43,580 shares in the company, valued at approximately $3,646,338.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Lilly Endowment Inc sold 180,000 shares of Eli Lilly and stock in a transaction on Thursday, August 31st. The shares were sold at an average price of $81.06, for a total transaction of $14,590,800.00. Following the completion of the sale, the insider now owns 123,865,804 shares in the company, valued at $10,040,562,072.24. The disclosure for this sale can be found here. Insiders sold a total of 772,003 shares of company stock worth $64,837,441 over the last quarter. Company insiders own 0.20% of the company’s stock.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.